A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. The metric has seen a significant gain of 638.22% since the start of this calendar year. Looking back over the last six months, we can see a weaker performance of 309.95%. Over the past 30 days, the price of SMMT has leaped by -4.14%. And in the last five days, it has fallen by -3.81%.
Summit Therapeutics Inc ‘s stock market performance has been somewhat predictable. The company’s stock reached a 1-year high price of $33.89 on 09/16/24, while the lowest value for the same period was recorded at $1.64 on 11/09/23.
52-week price history of SMMT Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Summit Therapeutics Inc’s current trading price is -43.15% away from its 52-week high, while its distance from the 52-week low is 1074.85%. The stock’s price range during this period has varied between$1.64 and $33.89. The Summit Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 1.69 million for the day, a figure considerably lower than their average daily volume of 5.01 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Summit Therapeutics Inc (SMMT) has experienced a quarterly rise of 80.75% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 13.96B and boasts a workforce of 105 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 14.53, with a change in price of +11.65. Similarly, Summit Therapeutics Inc recorded 4,136,790 in trading volume during the last 100 days, posting a change of +150.84%.
SMMT’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for SMMT stands at 0.56. Similarly, the long-term debt-to-equity ratio is also 0.03.
SMMT Stock Stochastic Average
Summit Therapeutics Inc’s raw stochastic average for the past 50 days is presently 34.37%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 19.33%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 46.97% and 49.42%, respectively.
